AnnJi Pharmaceutical (AnnJi) announced on the 22nd that its rare disease therapy AJ201 for Kennedy’s disease/Spinal and Bulbar Muscular Atrophy (SBMA) has been granted Fast Track Designation (FTD) by the U.S. FDA. AJ201 had previously received Orphan Drug Designations (ODD) from both the FDA and the European Medicines Agency (EMA).

The Fast Track Designation (FTD) is a key regulatory incentive by the U.S. FDA designed to accelerate the development and review of potential new therapies, particularly for drugs addressing rare or serious diseases with unmet medical needs, enabling patients to access innovative treatments more quickly.

Wendy Huang, Chairperson and CEO of AnnJi Pharmaceutical, stated that receiving FDA Fast Track status allows for more frequent consultations and written communications with the agency. During Phase III clinical trials, the company can pre-submit documents required for the New Drug Application (NDA) under the Rolling Review mechanism. AJ201 may also benefit from Accelerated Approval and Priority Review if FDA requirements are met. The goal is to expedite clinical development, achieve regulatory approval, and provide patients with the first approved therapy for this disease in 20 years.

Spinal and Bulbar Muscular Atrophy (SBMA, or Kennedy’s Disease) is a rare, severe genetic neuromuscular degenerative disorder caused by the degeneration of lower motor neurons in the brainstem and spinal cord. It progressively weakens limb and bulbar muscles, affecting walking, speaking, chewing, and swallowing, and may lead to respiratory complications. Globally, approximately 1 in 40,000 men is affected, and currently no FDA-approved treatments exist.

The pathogenic mechanism of SBMA arises from abnormal expansion of the CAG trinucleotide repeat in the androgen receptor (AR) gene, producing a mutant AR protein with an elongated polyglutamine (PolyQ) tract. Accumulation of this mutant protein induces cytotoxicity, oxidative stress, and chronic neuroinflammation, ultimately causing muscle atrophy and neuron death.

AJ201 (active ingredient JM17) is a novel small-molecule drug that has demonstrated the potential to improve motor function and reduce mutant AR toxicity in SBMA animal models. Mechanistically, JM17 promotes degradation of the mutant AR protein while inducing expression of antioxidant enzymes, proteasome subunits, and heat shock proteins, helping to slow disease progression.

Resource: 安基罕病新藥AJ201 獲美國FDA授予快速審查認定